Cited by 1,967Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 168 of the 169 references it cites were found in a registry or an index.

The first 30 years of p53: growing ever more complex.

Open access

Levine, Arnold J., Oren, Moshe·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Thirty years ago p53 was discovered as a cellular partner of simian virus 40 large T-antigen, the oncoprotein of this tumour virus. The first decade of p53 research saw the cloning of p53 DNA and the realization that p53 is not an oncogene but a tumour suppressor that is very frequently mutated in human cancer. In the second decade of research, the function of p53 was uncovered: it is a transcription factor induced by stress, which can promote cell cycle arrest, apoptosis and senescence. In the third decade after its discovery new functions of this protein were revealed, including the regulation of metabolic pathways and cytokines that are required for embryo implantation. The fourth decade of research may see new p53-based drugs to treat cancer. What is next is anybody's guess.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc2723

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“More recently, induction of cellular senescence was identified as an additional mechanism whereby p53 curbs neoplastic processe”
p53, guardian of the genome
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Self-citation
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Self-citation
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

Flagged first, then by citations

Show all 169 references

1 of the 169 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 1,002

p53: From Fundamental Biology to Clinical Applications in Cancer
Capuozzo, M., Santorsola, M., Bocchetti, M., Perri, F., Cascella, M., Granata, V., Celotto, V., Gualillo, O., Cossu, A. M., Nasti, G., et al. (2022) · Biology · doi:10.3390/biology11091325 · Cited by 74
FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX
Ling, X., Xu, C., Fan, C., Zhong, K. L., Li, F., & Wang, X. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0683 · Cited by 70
The p53-MDM2/MDMX axis – A chemotype perspective
Khoury, K., Popowicz, G. M., Holak, T. A., & Dömling, A. S. S. (2011) · MedChemComm · doi:10.1039/c0md00248h · Cited by 71
Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression
Yan, W., Zhang, Y., Jin, Z., Liu, S., Cho, S. J., & Chen, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.231639 · Cited by 71
Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden
Ji, J., Sundquist, K., & Sundquist, J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70132-8 · Cited by 71
METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53‐wild‐type cells
Hou, Y., Zhang, X., Yao, H., Hou, L., Zhang, Q., Tao, E., Zhu, X., Jiang, S., Ren, Y., Hong, X., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256325 · Cited by 69
State-of-the-art review of theabrownins: from preparation, structural characterization to health-promoting benefits
Cheng, L., Wei, Y., Peng, L., Wei, K., Liu, Z., & Wei, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2236701 · Cited by 68
p53: A tale of complexity and context
Oren, M., & Prives, C. L. (2024) · Cell · doi:10.1016/j.cell.2024.02.043 · Cited by 71
Self-citation
A biomimetic polyketide-inspired approach to small-molecule ligand discovery
Aquino, C., Sarkar, M., Chalmers, M. J., Mendes, K., Kodadek, T. J., & Micalizio, G. C. (2011) · Nature Chemistry · doi:10.1038/nchem.1200 · Cited by 70
Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress
McDade, S. S., Patel, D., Moran, M., Campbell, J., Fenwick, K., Kozarewa, I., Orr, N., Lord, C. J., Ashworth, A., & McCance, D. J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku299 · Cited by 71
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT
Wei, J., Xiao, M., Mao, Z., Wang, N., Cao, Y., Xiao, Y., Meng, F., Sun, W., Wang, Y., Yang, X., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00924-0 · Cited by 68
Expression and inactivation of glycogen synthase kinase 3 alpha/ beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression
Mishra, R., Nagini, S., & Rana, A. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0300-x · Cited by 70
Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes
Penna, G., Vaisman, F., Vaisman, M., Sobrinho-Simões, M. A., & Soares, P. (2016) · Cytogenetic and Genome Research · doi:10.1159/000456576 · Cited by 66
SPIN1 promotes tumorigenesis by blocking the uL18 (universal large ribosomal subunit protein 18)-MDM2-p53 pathway in human cancer
Fang, Z., Cao, B., Liao, J., Deng, J., Plummer, K. D., Liao, P., Liu, T., Zhang, W., Zhang, K., Li, L., et al. (2018) · eLife · doi:10.7554/elife.31275 · Cited by 68
p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53
Zhou, Y., Niu, W., Luo, Y., Li, H., Xie, Y., Wang, H., Liu, Y., Fan, S., Li, Z., Xiong, W., et al. (2019) · Cancer Science · doi:10.1111/cas.13928 · Cited by 66
P53 in skin cancer: From a master player to a privileged target for prevention and therapy
Loureiro, J. B., Abrantes, A. M., Oliveira, P. A., & Saraiva, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188438 · Cited by 69
Maternal exposure to nanopolystyrene induces neurotoxicity in offspring through P53-mediated ferritinophagy and ferroptosis in the rat hippocampus
Chen, J., Yan, L., Zhang, Y., Liu, X., Wei, Y., Zhao, Y., Li, K., Shi, Y., Liu, H., Lai, W., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02911-9 · Cited by 75
Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes?
Tacar, O., & Dass, C. R. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12144 · Cited by 67
microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network
Hoffman, Y., Pilpel, Y., & Oren, M. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju020 · Cited by 65
Self-citation
The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment
Yaffe, M. B. (2013) · Science Signaling · doi:10.1126/scisignal.2003684 · Cited by 67
TP53mutations are frequent events in double-hit B-cell lymphomas withMYCandBCL2but notMYCandBCL6translocations
Gebauer, N., Bernard, V., Gebauer, W., Thorns, C., Feller, A. C., & Merz, H. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.907896 · Cited by 67
Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis
Cordani, M., Pacchiana, R., Butera, G., D’Orazi, G., Scarpa, A., & Donadelli, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.046 · Cited by 70
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis
Fischer, N. W., Prodeus, A., Malkin, D. M., & Gariépy, J. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1241917 · Cited by 67
Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53
Yu, X., Blanden, A. R., Tsang, A. T., Zaman, S., Liu, Y., Gilleran, J., Bencivenga, A. F., Kimball, S. D., Loh, S. N., & Carpizo, D. R. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107409 · Cited by 66
Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional targetPreprint
Watanabe, H., Francis, J. M., Woo, M. S., Etemad, B., Lin, W., Fries, D. F., Peng, S., Snyder, E. L., Tata, P. R., Izzo, F., et al. (2013) · Genes & Development · doi:10.1101/gad.203208.112 · Cited by 64
Dysfunctional autophagy induced by the pro-apoptotic natural compound climacostol in tumour cells
Zecchini, S., Serafini, F. P., Catalani, E., Giovarelli, M., Coazzoli, M., Renzo, I. D., Palma, C. D., Perrotta, C., Clementi, E., Buonanno, F., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1254-x · Cited by 71
p53’s Extended Reach: The Mutant p53 Secretome
Pavlakis, E., & Stiewe, T. (2020) · Biomolecules · doi:10.3390/biom10020307 · Cited by 66
Non-coding small nucleolar RNA SNORD17 promotes the progression of hepatocellular carcinoma through a positive feedback loop upon p53 inactivation
Liang, J., Li, G., Liao, J., Huang, Z., Wen, J., Wang, Y., Chen, Z., Cai, G., Xu, W., Ding, Z., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00929-w · Cited by 65
Annexin A11 in disease
Wang, J.-S., Guo, C., Liu, S., Qi, H., Yin, Y., Liang, R., Sun, M., & Greenaway, F. T. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.031 · Cited by 65
Annexin A2 and PSF proteins interact with p53 IRES and regulate translation of p53 mRNA
Arandkar, S., Lal, R., Khan, D., & Das, S. (2012) · RNA Biology · doi:10.4161/rna.22707 · Cited by 71
Gambogic acid triggers DNA damage signaling that induces p53/p21Waf1/CIP1 activation through the ATR-Chk1 pathway
Rong, J., Hu, R., Song, X., Ha, J., Lu, N., Qi, Q., Tao, L., You, Q., & Guo, Q. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.016 · Cited by 65
GRWD1 negatively regulates p53 via the RPL11–MDM2 pathway and promotes tumorigenesis
Kayama, K., Watanabe, S., Takafuji, T., Tsuji, T., Hironaka, K., Matsumoto, M., Nakayama, K. I., Enari, M., Kohno, T., Shiraishi, K., et al. (2016) · EMBO Reports · doi:10.15252/embr.201642444 · Cited by 65
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness
Olivos, D. J., & Mayo, L. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121982 · Cited by 67
Comparative transcriptome analysis of ovary and testis reveals potential sex-related genes and pathways in spotted knifejaw Oplegnathus punctatus
Du, X., Wáng, B., Liu, X., Liu, X., He, Y., Zhang, Q., & Wang, X. (2017) · Gene · doi:10.1016/j.gene.2017.09.055 · Cited by 64
Immunosenescence in atherosclerosis: A role for chronic viral infections
Talepoor, A. G., & Doroudchi, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945016 · Cited by 65
Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment
Wu, M., Zhao, Y., Zhang, C., & Pu, K. (2024) · ACS Nano · doi:10.1021/acsnano.4c09800 · Cited by 65
Sliding of p53 along DNA Can Be Modulated by Its Oligomeric State and by Cross-Talks between Its Constituent Domains
Khazanov, N., & Levy, Y. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.059 · Cited by 65
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 68
Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis
Xiong, X., Zhao, Y., Tang, F., Wei, D., Thomas, D. G., Wang, X., Liu, Y., Zheng, P., & Sun, Y. (2014) · eLife · doi:10.7554/elife.02236 · Cited by 66
Mechanisms of transcription factor evolution in Metazoa
Schmitz, J. F., Zimmer, F., & Bornberg‐Bauer, E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw492 · Cited by 62
Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis
Fernandez‐Pol, S., Ma, L., Ohgami, R. S., & Arber, D. A. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.206 · Cited by 63
Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression
Talib, W. H., & Kury, L. T. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.139 · Cited by 64
p53 is essential for DNA methylation homeostasis in naïve embryonic stem cells, and its loss promotes clonal heterogeneityPreprint
Tovy, A., Spiro, A., McCarthy, R. L., Shipony, Z., Aylon, Y., Allton, K. L., Ainbinder, E., Furth, N., Tanay, A., Barton, M. C., et al. (2017) · Genes & Development · doi:10.1101/gad.299198.117 · Cited by 64
Self-citation
Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation
Tanihara, F., Hirata, M., Nguyen, N. T., Le, Q. A., Hirano, T., Takemoto, T., Nakai, M., Fuchimoto, D.-I., & Otoi, T. (2018) · PLOS ONE · doi:10.1371/journal.pone.0206360 · Cited by 63
Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance
Xu, J., Patel, N. H., & Gewirtz, D. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238991 · Cited by 66
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Chen, S., Li, X., Li, Y., Xing, Y., Geng, C., Gao, S., Li, J., Ma, B., Wang, Z., Lu, W., et al. (2022) · Theranostics · doi:10.7150/thno.75444 · Cited by 64
The New Faces of Endocytosis in Signaling
Hupalowska, A., & Miączyńska, M. (2011) · Traffic · doi:10.1111/j.1600-0854.2011.01249.x · Cited by 61
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia
Ånensen, N., Hjelle, S. M., Belle, W. V., Haaland, I., Silden, E., Bourdon, J., Hovland, R., Taskén, K., Knappskog, S., Lønning, P. E., et al. (2011) · Oncogene · doi:10.1038/onc.2011.348 · Cited by 67
Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity
Quante, T., Otto, B., Brázdová, M., Kejnovská, I., Deppert, W., & Tolstonog, G. V. (2012) · Cell Cycle · doi:10.4161/cc.21646 · Cited by 65
SUMO-specific protease 2 in Mdm2-mediated regulation of p53
Jiang, M., Chiu, S.-Y., & Hsu, W. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.168 · Cited by 65
Drastic Effect of GermlineTP53Missense Mutations in Li-Fraumeni Patients
Zerdoumi, Y., Aury‐Landas, J., Bonaïti‐Pellié, C., Derambure, C., Sesboüé, R., Renaux‐Petel, M., Frébourg, T., Bougeard, G., & Flaman, J. (2012) · Human Mutation · doi:10.1002/humu.22254 · Cited by 63
The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation
Wu, Q., Madany, P., Akech, J., Dobson, J. R., Douthwright, S., Browne, G., Colby, J. L., Winter, G. E., Bradner, J. E., Pratap, J., et al. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24991 · Cited by 63
Cancer-mutated ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit
Cao, B., Fang, Z., Liao, P., Zhou, X. Y., Xiong, J., Zeng, S. X., & Lu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.21544 · Cited by 65
The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium
Rubisz, P., Ciebiera, M., Hirnle, L., Zgliczyńska, M., Łoziński, T., Dzięgiel, P., & Kobierzycki, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051136 · Cited by 64
Glycogen synthase kinase 3 promotes p53 mRNA translation via phosphorylation of RNPC1Preprint
Zhang, M., Zhang, J., Chen, X., Cho, S.-J., & Chen, X. (2013) · Genes & Development · doi:10.1101/gad.221739.113 · Cited by 65
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
de Weger, V. A., de Jonge, M., Langenberg, M. H. G., Schellens, J. H. M., Lolkema, M., Varga, A., Demers, B., Thomas, K., Hsu, K., Tuffal, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0355-8 · Cited by 62
Cancer‐specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis
Candeias, M. M., Hagiwara, M., & Matsuda, M. (2016) · EMBO Reports · doi:10.15252/embr.201541956 · Cited by 64
Topological identification and interpretation for single-cell gene regulation elucidation across multiple platforms using scMGCA
Yu, Z., Su, Y., Lu, Y., Yang, Y., Wang, F., Zhang, S., Chang, Y., Wong, K., & Li, X. (2023) · Nature Communications · doi:10.1038/s41467-023-36134-7 · Cited by 59
RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38
Weilbacher, A., Gutekunst, M., Oren, M., Aulitzky, W. E., & van der Kuip, H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.284 · Cited by 62
Self-citation
Optimized Approaches for Generation of Integration-free iPSCs from Human Urine-Derived Cells with Small Molecules and Autologous Feeder
Li, D., Wang, L., Hou, J., Shen, Q., Chen, Q., Wang, X., Du, J., Cai, X., Shan, Y., Zhang, T., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.04.001 · Cited by 63
Sarcomas of Bone
Anderson, M. E., Randall, R. L., Springfield, D. S., & Gebhardt, M. C. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00092-8 · Cited by 59
40 Years of Research Put p53 in Translation
Marcel, V., Long, F. N. V., & Diaz, J. (2018) · Cancers · doi:10.3390/cancers10050152 · Cited by 61
Selective Cytotoxicity and Apoptosis-Induction of Cyrtopodion scabrum Extract Against Digestive Cancer Cell Lines
Rashidi, M., Seghatoleslam, A., Namavari, M., Amiri, A., Fahmidehkar, M. A., Ramezani, A., Eftekhar, E., Hosseini, A., Erfani, N., & Fakher, S. (2017) · International Journal of Cancer Management · doi:10.5812/ijcm.8633 · Cited by 60
Lovastatin‐mediated MCF‐7 cancer cell death involves LKB1‐AMPK‐p38MAPK‐p53‐survivin signalling cascade
Huang, S., Chyuan, I., Shiue, C., Yu, M., Hsu, Y., & Hsu, M. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14879 · Cited by 59
The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity
Tian, W., Wang, Y., Xu, Y., Guo, X., Wang, B., Sun, L., Liu, L., Cui, F., Zhuang, Q., Bao, X., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.538157 · Cited by 59
TP53 Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer
Pan, M., Jiang, C., Tse, P., Achacoso, N., Alexeeff, S., Solorzano, A. V., Chung, E., Hu, W., Truong, T.-G., Arora, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02014 · Cited by 59
Loss of p53 and altered miR15-a/16-1→MCL-1 pathway in CLL: insights from TCL1-Tg:p53−/− mouse model and primary human leukemia cells
Liu, J., Chen, G., Feng, L., Zhang, W., Pelicano, H., Wang, F., Ogasawara, M. A., Lu, W., Amin, H. M., Croce, C. M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.125 · Cited by 59
SPATA18, a Spermatogenesis-Associated Gene, Is a Novel Transcriptional Target of p53 and p63
Bornstein, C., Brosh, R., Molchadsky, A., Madar, S., Kogan-Sakin, I., Goldstein, I., Chakravarti, D., Flores, E. R., Goldfinger, N., Sarig, R., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01072-10 · Cited by 63
Common genetic variants in the TP53 pathway and their impact on cancer
Barnoud, T., Parris, J. L. D., & Murphy, M. E. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz052 · Cited by 62
Effect of Lactobacillus acidophilus CICC 6074 S-Layer Protein on Colon Cancer HT-29 Cell Proliferation and Apoptosis
Zhang, T., Pan, D., Yang, Y., Jiang, X., Zhang, J., Zeng, X., Wu, Z. F., Sun, Y., & Guo, Y. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b06909 · Cited by 59
Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells
Rothweiler, F., Michaelis, M., Brauer, P., Otte, J., Riecken, K., Fehse, B., Doerr, H. W., Wiese, M., Kreuter, J., Al‐Abed, Y., et al. (2010) · Neoplasia · doi:10.1593/neo.10856 · Cited by 58
Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification
Notari, M., Hu, Y., Koch, S., Lu, M. M., Ratnayaka, I., Zhong, S., Baer, C., Pagotto, A., Goldin, R. D., Salter, V., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102292108 · Cited by 58
Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance
Belle, J. I., Petrov, J. C., Langlais, D., Robert, F., Cencic, R., Shen, S., Pelletier, J., Gros, P., & Nijnik, A. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2015.140 · Cited by 62
Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway
Yuan, W., Li, T., Mo, X., Wang, X., Liu, B., Wang, W., Su, Y., Xu, L., & Han, W. (2016) · Oncotarget · doi:10.18632/oncotarget.8789 · Cited by 59
Exploring Dysregulated Signaling Pathways in Cancer
Nisar, S., Hashem, S., Macha, M. A., Yadav, S. K., Muralitharan, S., Therachiyil, L., Sageena, G., Al‐Naemi, H. A., Haris, M., & Bhat, A. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200115095937 · Cited by 60
p53 Isoforms in Cellular Senescence- and Ageing-Associated Biological and Physiological Functions
Fujita, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236023 · Cited by 59
Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors
Huang, X., Cao, Z., Qian, J., Ding, T., Wu, Y., Zhang, H., Zhong, S., Wang, X., Ren, X., Zhang, W., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01562-5 · Cited by 64
p53 isoforms gain functions
Olivares‐Illana, V., & Fåhræus, R. (2010) · Oncogene · doi:10.1038/onc.2010.266 · Cited by 58
To be, or not to be
Wang, S.-J., & Gu, W. J. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000024 · Cited by 58
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 58
Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
Kung, C.-P., Khaku, S., Jennis, M., Zhou, Y., & Murphy, M. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0385 · Cited by 58
Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein, Y., Aloni-Grinstein, R., & Rotter, V. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa117 · Cited by 62
Anti-Proliferative and Apoptosis-Inducing Effect of Theabrownin against Non-small Cell Lung Adenocarcinoma A549 Cells
Wu, F., Zhou, L., Jin, W., Yang, W., Wang, Y., Yan, B., Du, W., Zhang, Q., Zhang, L., Guo, Y., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00465 · Cited by 55
Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics
Abe, I., & Lam, A. K.-Y. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01019-9 · Cited by 57
TP53 dysfunction in diffuse large B-cell lymphoma
Lu, T., Young, K. H., Xu, W., & Li, J.-Y. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.006 · Cited by 58
Interleukin 7 signaling prevents apoptosis by regulating bcl-2 and bax via the p53 pathway in human non-small cell lung cancer cells.
Liu, Z., Wang, M., Ren, H., Qü, W., Sun, L., Zhang, Q.-F., Qiu, X.-S., & Wang, E. (2014) · Europe PMC (PubMed Central) · Cited by 56
p53 suppresses carcinoma progression by inhibiting mTOR pathway activation
Akeno, N., Miller, A. L., Ma, X., & Wikenheiser‐Brokamp, K. A. (2014) · Oncogene · doi:10.1038/onc.2013.589 · Cited by 57
Molecular mechanisms of hepatic apoptosis regulated by nuclear factors
Wang, K. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.11.038 · Cited by 56
MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma
Brandetti, E., Veneziani, I., Melaiu, O., Pezzolo, A., Castellano, A., Boldrini, R., Ferretti, E., Fruci, D., Moretta, L., Pistoia, V., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1316439 · Cited by 56
Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers
Ferraiuolo, M. A., Verduci, L., Blandino, G., & Strano, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050961 · Cited by 56
p53 in Bronchial Club Cells Facilitates Chronic Lung Inflammation by Promoting Senescence
Sagiv, A., Bar-Shai, A., Levi, N., Hatzav, M., Zada, L., Ovadya, Y., Roitman, L., Manella, G., Regev, O., Majewska, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.009 · Cited by 55
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
Saiki, A. Y., Caenepeel, S., Yu, D., Lofgren, J. A., Osgood, T., Robertson, R., Canon, J., Su, C., Jones, A., Zhao, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1918 · Cited by 55
MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling
Zhang, C., Liu, J., Wang, X., Wu, R., Lin, M., Laddha, S. V., Yang, Q., Chan, C. S., & Feng, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2379 · Cited by 55
A Comprehensive Review of Ovarian Serous Carcinoma
Hatano, Y., Hatano, K., Tamada, M., Morishige, K.-I., Tomita, H., Yanai, H., & Hara, A. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000243 · Cited by 56
Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1α/XBP1 pathway
Namba, T., Chu, K., Kodama, R., Byun, S., Yoon, K. W., Hiraki, M., Mandinova, A., & Lee, S. W. (2015) · Oncotarget · doi:10.18632/oncotarget.4598 · Cited by 55
Gene Expression and DNA-Methylation of Bovine Pretransfer Endometrium Depending on Its Receptivity after In Vitro-Produced Embryo Transfer
Ponsuksili, S., Muráni, E., Schwerin, M., Schellander, K., Tesfaye, D., & Wimmers, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042402 · Cited by 59
Ribosomal proteins L11 and L5 activate TAp73 by overcoming MDM2 inhibition
Zhou, X. Y., Hao, Q., Zhang, Q., Jm, L., Jw, K., Liao, P., Cao, B., & Lu, H. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.167 · Cited by 55
miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma
Bennett, P., Bemis, L., Norris, D. A., & Shellman, Y. G. (2013) · Physiological Genomics · doi:10.1152/physiolgenomics.00116.2013 · Cited by 56
Epigenetic Applications in Adverse Outcome Pathways and Environmental Risk Evaluation
Angrish, M. M., Allard, P., McCullough, S. D., Druwe, I. L., Chadwick, L. H., Hines, E. P., & Chorley, B. N. (2018) · Environmental Health Perspectives · doi:10.1289/ehp2322 · Cited by 57
Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus
Song, S., Shi, Y., Wu, W., Wu, H., Chang, L., Peng, P., Zhang, L., Fan, J., Gu, J., & Ruan, Y. (2020) · Gut · doi:10.1136/gutjnl-2020-321386 · Cited by 53

Authors: Levine, A. J., & Oren, M.
Affiliations: Institute for Advanced Study (US)
Weizmann Institute of Science (IL)
ORCID: Levine, Arnold J.
Oren, Moshe
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-10
Volume: 9
Issue: 10
Pages: 749-758
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2723
PMC: PMC2771725
OpenAlex: W1966163762
Cited by: 1,967
References: 169
Citations by year: 2026: 64 · 2025: 111 · 2024: 107 · 2023: 112 · 2022: 114 · 2021: 129 · 2020: 128 · 2019: 111 · 2018: 127 · 2017: 120 · 2016: 144 · 2015: 115 · 2014: 150 · 2013: 113 · 2012: 170
FWCI: 9.34
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P01CA087497, R37 CA40099, R37CA040099, P01CA87497.)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: p53, TP53, tumour suppressor, SV40 large T antigen, transcription factors, cell cycle arrest, apoptosis, cellular senescence, metabolic regulation, cytokine regulation, embryo implantation
MeSH terms: Animals, Humans, Neoplasms, Genes, p53, Tumor Suppressor Protein p53, History, 20th Century, History, 21st Century

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The first 30 years of p53: growing ever more complex.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks